After readjudication of the endpoints, the incidence rate of HIV- person-years was 0.37 with Apretude vs. 1.22 with Truvada (HR
Apretude Injectable PrEP is effective in reducing your risk of HIV. Compared to oral PrEP treatment by Truvada, injectable PrEP by Apretude was
In two Apretude clinical trials with over 7,700 participants, Apretude was proven superior to daily oral Truvada (emtricitabine / tenofovir disoproxil fumarate) in reducing the risk of acquiring HIV. In these 2 studies, those receiving Apretude had a 69% and a 90% lower incidence of HIV compared to those receiving Truvada tablets.
In clinical trials, Apretude was superior to Truvada in preventing new HIV infections in men who have sex with men and transgender or cisgender women. Apretude
on APRETUDE vs TRUVADA during the study. IMPORTANT SAFETY INFORMATION (cont d) Before receiving APRETUDE, tell your healthcare provider about all your medical conditions, including if you: (cont d) are pregnant or plan to become pregnant. It is not known if APRETUDE will harm your unborn
APRETUDE compared with TRUVADA. There is no head-to-head comparison between APRETUDE and DESCOVY. On Decem, the Food and Drug Administration
Apretude (cabotegravir extended-release injectable suspension), Descovy (emtricitabine and tenofovir alafenamide), and Truvada (emtricitabine
Daily Pills vs. Injectable PrEP Traditional PrEP methods, like Truvada and Descovy, require daily oral intake. In contrast, Apretude is administered as an
☐ Medication is Truvada (tenofovir-emtricitabine), Descovy (emtricitabine and tenofovir alafenamide) or Apretude (cabotegravir); and. ☐ No
Look it up. It reduces risk of transmission markedly